Zobrazeno 1 - 10
of 1 255
pro vyhledávání: '"Dafna D. Gladman"'
Autor:
Jeffrey R. Curtis, Atul Deodhar, Enrique R. Soriano, Emmanouil Rampakakis, May Shawi, Natalie J. Shiff, Chenglong Han, William Tillett, Dafna D. Gladman
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 6, Pp 1501-1517 (2024)
Abstract Introduction Patterns of treatment response can inform clinical decision-making. This study assessed the course and impact of achieving minimal clinically important improvement (MCII) in clinical measures and patient-reported outcomes (PROs)
Externí odkaz:
https://doaj.org/article/631e6dc4cc6a4bb893e0571db9fd29f2
Autor:
Alexis Ogdie, Lars E. Kristensen, Enrique R. Soriano, Servet Akar, Yanhui Sun, David Gruben, Lara Fallon, Cassandra D. Kinch, Dafna D. Gladman
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 6, Pp 1649-1664 (2024)
Abstract Introduction Routine care studies of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) demonstrated attenuated responses to tumor necrosis factor inhibitors in current/past versus never smokers. This post hoc analysis assessed tofaci
Externí odkaz:
https://doaj.org/article/e7e37982bed941ab871e32ad56487ec9
Autor:
Dafna D Gladman, Murray Urowitz, Zahi Touma, Raphael Schneider, Joan Wither, Dennisse Bonilla, Laura Patricia Whittall Garcia
Publikováno v:
Lupus Science and Medicine, Vol 11, Iss 2 (2024)
Objective To determine if serum interferon (IFN)-α levels at the time of a lupus nephritis (LN) flare are associated with renal outcomes.Methods Patients with an LN flare who had a preflare estimated glomerular filtration rate (eGFR) ≥60 mL/min we
Externí odkaz:
https://doaj.org/article/8dc67a8259ba49a9b38295398904b763
Publikováno v:
RMD Open, Vol 10, Iss 4 (2024)
Objectives Chronic kidney disease (CKD) is a comorbidity in psoriatic arthritis (PsA). We aimed to define the prevalence of CKD in patients with PsA, describe their long-term renal outcomes and identify risk factors for CKD development.Methods We inc
Externí odkaz:
https://doaj.org/article/88a77c777b244e7286cedb92e74d8c75
Autor:
Lars Erik Kristensen, Atul Deodhar, Ying-Ying Leung, Ivana Vranic, Mahta Mortezavi, Lara Fallon, Arne Yndestad, Cassandra D. Kinch, Dafna D. Gladman
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 487-499 (2024)
Abstract In this commentary, we review clinical data which helps inform individualized benefit–risk assessment for tofacitinib in patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS). ORAL Surveillance, a safety trial of patients
Externí odkaz:
https://doaj.org/article/0dfdf61802f742879087a07fe9f0706d
Autor:
Joseph F Merola, Philip J Mease, Dafna D Gladman, M Elaine Husni, Nadine Goldammer, Jason Coarse, William Tillett, Vanessa Taieb, Jeremy Lambert, Barbara Ink
Publikováno v:
RMD Open, Vol 10, Iss 3 (2024)
Objectives To assess impact of bimekizumab treatment on patient-reported outcomes and health-related quality of life (HRQoL) in patients with active psoriatic arthritis (PsA), using 16-week data from two phase 3 studies.Methods BE OPTIMAL (NCT0389520
Externí odkaz:
https://doaj.org/article/6b47e439da8445b083e973aca1ddd188
Autor:
Vinod Chandran, Louis Bessette, Carter Thorne, Maqbool Sheriff, Proton Rahman, Dafna D. Gladman, Sabeen Anwar, Jennifer Jelley, Anne-Julie Gaudreau, Manprit Chohan, John S. Sampalis
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 2, Pp 443-455 (2024)
Abstract Introduction The APPRAISE study was conducted to better understand the 12-month effectiveness, tolerability, and patient satisfaction with apremilast treatment for patients with psoriatic arthritis (PsA) in real-world settings. Methods APPRA
Externí odkaz:
https://doaj.org/article/e0c68fb386474728b01333870b8c7130
Autor:
Jeffrey R. Curtis, Iain B. McInnes, Proton Rahman, Dafna D. Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P. Kollmeier, Natalie J. Shiff, Chenglong Han, May Shawi, William Tillett, Philip J. Mease
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 2, Pp 425-441 (2024)
Abstract Introduction To evaluate the effect of guselkumab on work productivity and nonwork daily activity impairment and general health status through 2 years in patients who were biologic-naïve with active psoriatic arthritis (PsA) in the phase 3
Externí odkaz:
https://doaj.org/article/0fe4fa79267340eca6264c7603694203
Autor:
Philip J. Mease, Dafna D. Gladman, Denis Poddubnyy, Soumya D. Chakravarty, May Shawi, Alexa P. Kollmeier, Xie L. Xu, Stephen Xu, Atul Deodhar, Xenofon Baraliakos
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 6, Pp 1637-1653 (2023)
Abstract Introduction Guselkumab previously showed greater improvements versus placebo in axial symptoms in patients with psoriatic arthritis (PsA) (assessed by Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] and Ankylosing Spondylitis Di
Externí odkaz:
https://doaj.org/article/78e3cd32eadf45c68aebb23a5cc1f2fa
Autor:
Robert Landewé, Joseph F Merola, Laure Gossec, Frank Behrens, Ana-Maria Orbai, Philip J Mease, Iain B McInnes, Dafna D Gladman, Laura C Coates, Alice B Gottlieb, Vishvesh Shende, Jason Coarse, Christopher T Ritchlin, Richard B Warren, Akihiko Asahina, Barbara Ink, Rajan Bajracharya
Publikováno v:
RMD Open, Vol 10, Iss 1 (2024)
Objectives To assess 52-week safety and efficacy of bimekizumab in patients with active psoriatic arthritis (PsA) and prior inadequate response/intolerance to tumour necrosis factor inhibitors.Methods Patients completing the 16-week phase III double-
Externí odkaz:
https://doaj.org/article/8c6f7873019c4474b1623173fd071db0